Cancer Clinical Trial
Official title:
Clinical Utilization of Newly Approved Oncology Medications in Middle Eastern Population
The efficacy and safety of different medications vary from one individual to another and
from one ethnic group to another. Therefore, strong interest in the study of pharmacogenomic
and pharmacoepidemiology has evolved recently.
There are multiple examples of oncology drugs being more effective in certain ethnic
population compared to other. For example, irinotecan combined with cisplatin was very
effective drug in the management of small cell lung cancer in the Japanese patients while an
identical study done in the US revealed no major benefit to this combination in American
population
Another example is having more benefit drawn from tyrosine kinase inhibitors (Erlotinib or
Gefitinib) in Asian patients.
Immunotherapy is a new class of cancer treatment that works to harness the innate powers of
the immune system to fight cancer. Because of the immune system's unique properties, these
therapies may hold greater potential than current treatment approaches to fight cancer more
powerfully, to offer longer-term protection against the disease, to come with fewer side
effects, and to benefit more patients with more cancer types
Immunotherapy includes treatments that work in different ways. Some boost the body's immune
system in a very general way. Others help train the immune system to attack cancer cells
specifically. Immunotherapy has become an important part of treating some types of cancer.
Newer types of immune treatments are now being studied, and they'll impact how we treat
cancer in the future.
Recently, multiple immunotherapy treatment been approved with a couple of EGFR resistant
medications.
Many new oncology drugs are being used in Middle Eastern countries including Saudi Arabia
for different indications without being studied in the Middle Eastern population. These
medications' efficacy and safety profiles may differ from those patients studied for drug
development and approval due to difference in population's characteristics.
The goal of this study is to observe, summarize and report the patterns of the use of these
drugs and describe their efficacy and safety profile in the early phases of their use.
The investigators aim is to build on the existing experience and knowledge by utilization of
classic methodology and approaches on a larger scale and more effective way to paint picture
of the performance of a certain therapy in the real life world. The use of prospective
design will help evaluate the efficacy and safety of therapies already used in practice,
generate new hypothesis, and/or determine the outcome of certain diseases.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|